Latest News

Steve Hughes, MD  (Credit: Avidity)
FDA Grants Rare Pediatric Disease Designation to Duchenne Agent AOC 1044 for Mutations Amenable to Exon 44 Skipping

May 19th 2024

Avidity Biosciences anticipates to provide new cohort data from the phase 1/2 EXPLORE44 trial assessing AOC 1044 in Duchenne muscular dystrophy mutations amenable to exon 44 skipping in the second half of 2024.

NeurologyLive® Brain Games: May 19, 2024
NeurologyLive® Brain Games: May 19, 2024

May 19th 2024

Reviewing Ravulizumab’s Long-Term Profile as New NMOSD Treatment
Reviewing Ravulizumab’s Long-Term Profile as New NMOSD Treatment

May 18th 2024

Biogen, Ionis Terminate BIIB105 Following Disappointing Phase 1/2 Results
Biogen, Ionis Terminate BIIB105 Following Disappointing Phase 1/2 Results

May 18th 2024

NeurologyLive® Friday 5 — May 17, 2024
NeurologyLive® Friday 5 — May 17, 2024

May 17th 2024

Coverage of the 2024 American Academy of Neurology Annual Meeting

Get the latest data and clinical news updates, as well as interviews with experts, straight from the conference floor of the AAN Annual Meeting.

AAN 2024

Conference Coverage

View All
Reviewing Ravulizumab’s Long-Term Profile as New NMOSD Treatment
Reviewing Ravulizumab’s Long-Term Profile as New NMOSD Treatment

May 18th 2024

CMSC 2024: What to Expect From This Year's Annual Meeting
CMSC 2024: What to Expect From This Year's Annual Meeting

May 15th 2024

NeuroVoices: Jessica Ailani, MD, on Implications of DELIVER Analysis With Eptinezumab for Migraine Prevention
NeuroVoices: Jessica Ailani, MD, on Implications of DELIVER Analysis With Eptinezumab for Migraine Prevention

May 15th 2024

Adding New Mechanistic Agents to SMA Treatment: the Phase 3 RESILIENT Study
Adding New Mechanistic Agents to SMA Treatment: the Phase 3 RESILIENT Study

May 13th 2024

Video Series
Video Interviews
Podcasts

Most Recent

© 2024 MJH Life Sciences

All rights reserved.